The Dana Farber Consortium Protocol for the Treatment of Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Single Institution Experience in Saudi Arabia

Micro-Abstract In this retrospective study we sought to evaluate the feasibility of using the Dana Farber Consortium Protocol in Saudi adolescents and young adult patients with acute lymphoblastic leukemia. The 3-year leukemia-free survival and overall survival rates were 70.2% and 72.5%, respective...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2017-05, Vol.17 (5), p.320-325
Hauptverfasser:	Alabdulwahab, Amal S, Elsayed, Hussein G, Sherisher, Mohamed A, Elbjeirami, Wafa M, Alieldin, Nelly
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute leukemia Adolescent Antineoplastic Combined Chemotherapy Protocols - therapeutic use AYA Chemotherapy DFCP Female Hematology, Oncology and Palliative Medicine Humans Male Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Retrospective Studies Saudi Arabia Toxicity Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Micro-Abstract In this retrospective study we sought to evaluate the feasibility of using the Dana Farber Consortium Protocol in Saudi adolescents and young adult patients with acute lymphoblastic leukemia. The 3-year leukemia-free survival and overall survival rates were 70.2% and 72.5%, respectively. Toxicities included infection, mortality during induction, and pancreatitis, but the incidence and severity of osteonecrosis were less than in Western populations, and no venous thromboembolism was found with the use of enoxaparin prophylaxis.
ISSN:	2152-2650 2152-2669
DOI:	10.1016/j.clml.2017.02.008